go-v.orgdoi

Telavancin in the treatment of nosocomial pneumonia: review of the clinical evidence

Admantia Liapikou, Laia Fernández‐Barat, Antoní Torres · Clinical Investigation · 2012

  • DOI 10.4155/cli.12.86
  • Publisher OMICS Publishing Group
  • Type article
  • Issued 2012

Not cached yet. This record was fetched live for this request and is stored after the lookup. Reopening the page should serve the cached copy.

Clinical Investigation · OMICS Publishing Group · article · 2012

Abstract

Nosocomial pneumonia (NP) is a frequent and severe infection arising mainly in intensive care units. Despite recent advances in supportive care and a wide range of prevention measures, it remains a significant cause of patient morbidity and mortality. A risk factor for increased mortality is the inappropriate antimicrobial therapy, often caused by antimicrobial resistance. The increased frequency of multidrug-resistant bacteria, especially methicillin-resistant Staphylococcus aureus and vancomycin-resistant strains, has led to an urgent need for new antibiotics.

Telavancin is a novel antibiotic-semisynthetic lipoglycopeptide, which deploys a dual mechanism of action that involves the inhibition of cell-wall synthesis and disruption of bacterial cell-membrane barrier functions and is rapidly bactericidal against methicillin-resistant S. aureus and Gram-positive bacteria resistant to vancomycin. It has been approved for the treatment of severe NP. This article reviews telavancin’s pharmacological characteri...

Open the resolved locator · 10.4155/cli.12.86

Metadata licence: OpenAlex metadata (CC0)

Registry
OpenAlex DOI index + API
Fetched
2026-11-20 00:34 UTC
Cache state
not cached yet (bulk-index+openalex)
Locator
https://doi.org/10.4155/cli.12.86
Metadata licence
OpenAlex metadata (CC0)
Scope
Metadata as returned by the resolver; abstracts are never generated here.